Such individuals often have clinical and metabolic features of type 2 diabetes, including high rates of obesity, a strong family history of diabetes, a measurable pancreatic insulin reserve, the absence of autoimmune markers of beta cell destruction, and the ability to discontinue insulin therapy during follow-up [14, 17]. This evidence concerns the gene INS and type 2 diabetes mellitus.